G Medical Innovations Holdings Ltd
OOTC:GMVDF0.00
USD
0.00
(0.00%)
ISIN
KYG394621414
CUSIP
G39462141
Return %
Stock
S&P 500
1Y
0.00
14.20
3Y
-99.71
81.12
5Y
-100.00
68.34
Capital Structure
USD
•
in mil. unless spec.Working Capital
USD
•
in mil. unless spec.Growth Rates
USD
•
in mil. unless spec.Semi-annual Revenue
USD
•
in mil. unless spec.Semi-annual Earnings Per Share
USD
•
in mil. unless spec.Semi-annual Dividends Per Share
USD
•
in mil. unless spec.Company Description
- CEO
- Yacov Geva
- Full Time Employees
- 84
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- 5 Oppenheimer Street Rehovot TA Israel 7670105
- IPO Date
- Oct 26, 2017
- Website
- gmedinnovations.com
- Similar Companies
- Business
- G Medical Innovations Holdings Ltd is an early commercial-stage healthcare company that develops and markets next-generation mobile health (mHealth), telemedicine solutions, and remote patient monitoring service platforms. The company offers clinical- and consumer-grade products including the Prizma multi-sensor medical smartphone case that transforms smartphones into vital signs monitoring devices for measuring parameters such as ECG, blood pressure, oxygen saturation, and temperature; the G Medical Spider, a compact one-piece mobile cardiac telemetry (MCT) patch device with built-in cellular modem for real-time dual-channel ECG transmission and up to five-day battery life; the G Patch extended Holter monitoring system, a multi-channel wearable biosensor recording two- or three-lead ECG for 72 hours to 14 days with waterproof design; and Wireless Vital Signs Monitoring System for continuous real-time biometrics tracking. It also provides patient monitoring services through independent diagnostic testing facilities (IDTFs) encompassing MCT, extended Holter, event, Holter, and pacemaker analysis; extended Holter patch services; and direct-to-consumer at-home laboratory testing kits covering food sensitivities, allergies, HPV, thyroid function, testosterone levels, hemoglobin A1C, and COVID-19-related diagnostics including rapid antigen, PCR, and antibody tests; alongside accessories for its devices. Operating through Products, Patient Services, and COVID-19 Testing and Kits segments, G Medical Innovations Holdings Ltd targets healthcare providers, physicians, hospitals, and consumers to enhance care efficiency, access, and personalization, with primary revenue from patient services and activities in the United States, Israel, and other markets. Founded in 2014 and headquartered at 5 Oppenheimer Street in Rehovot, Israel, with corporate registration in the Cayman Islands, the company employs approximately 74-84 staff and maintains subsidiaries for its operations. Recent developments include a May 2024 strategic partnership with fitness expert Peter N. Nielsen to advance health and wellness innovation through collaborative projects in education, solutions, and community engagement; an ongoing alliance with MiCare Path, extended through at least December 2024, to integrate hardware with software for enhanced remote patient monitoring and patient engagement; prior collaborations such as with AdventHealth serving 5.7 million patients annually; and preparations for launches including 31 at-home testing kits by late 2023, alongside reported 194% growth in home monitoring services earlier in 2023.